Shingles vaccine put to the test in frail patients

NCT ID NCT07321808

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how well the shingles vaccine works in people with weakened immune systems, such as those with cancer or autoimmune diseases. Researchers will measure immune responses and track side effects in 300 adults. The goal is to see if the vaccine can effectively prevent shingles in these vulnerable patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
recombinant zoster vaccine (RZV)
What this could lead to
If successful, this could show that the vaccine effectively prevents shingles in frail patients, leading to better vaccination guidelines for this group.
What could go wrong
This is an observational study, not a treatment trial. It may find that the vaccine works less well in some patients due to their weakened immune systems, and results may not apply to all frail populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONNECTIVE TISSUE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo, SC Microbiologia e Virologia

    RECRUITING

    Pavia, Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.